Lantheus (LNTH) Competitors

$85.82 -1.96 (-2.23%)

Closing price 04:00 PM Eastern

Extended Trading

$85.78 -0.04 (-0.05%)

As of 07:28 PM Eastern

LNTH vs. MRNA, ROIV, GMAB, SMMT, and VTRS

Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Moderna (MRNA), Roivant Sciences (ROIV), Genmab A/S (GMAB), Summit Therapeutics (SMMT), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Lantheus compare to Moderna?

Lantheus (NASDAQ:LNTH) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

: 99.1% of Lantheus shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: Lantheus has a beta of -0.08, meaning that its share price is 108% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
: Lantheus has a net margin of 15.15% compared to Moderna's net margin of -143.55%. Lantheus' return on equity of 30.77% beat Moderna's return on equity.
Company Net Margins Return on Equity Return on Assets
Lantheus 15.15% 30.77% 16.10%
Moderna -143.55% -26.64% -19.32%
: In the previous week, Moderna had 48 more articles in the media than Lantheus. MarketBeat recorded 53 mentions for Moderna and 5 mentions for Lantheus. Lantheus' average media sentiment score of 1.15 beat Moderna's score of 0.04 indicating that Lantheus is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lantheus
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Moderna
19 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
8 Negative mention(s)
5 Very Negative mention(s)
Neutral
: Lantheus presently has a consensus price target of $88.86, indicating a potential upside of 3.54%. Moderna has a consensus price target of $35.73, indicating a potential downside of 23.50%. Given Lantheus' stronger consensus rating and higher possible upside, analysts clearly believe Lantheus is more favorable than Moderna.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus
0 Sell rating(s)
3 Hold rating(s)

8 Buy rating(s)

0 Strong Buy rating(s)
2.73
Moderna
5 Sell rating(s)

12 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
1.84
: Lantheus has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lantheus $1.54B 3.62 $233.56M $3.37 25.47
Moderna $1.94B 9.49 -$2.82B -$8.15 N/A

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	15.15%	30.77%	16.10%
Moderna	-143.55%	-26.64%	-19.32%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	19 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	8 Negative mention(s)	5 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	3.62	$233.56M	$3.37	25.47
Moderna	$1.94B	9.49	-$2.82B	-$8.15	N/A

Summary

Lantheus beats Moderna on 11 of the 16 factors compared between the two stocks.

How does Lantheus compare to Roivant Sciences?

Lantheus (NASDAQ:LNTH) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

: 99.1% of Lantheus shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
: Lantheus has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.
: In the previous week, Roivant Sciences had 3 more articles in the media than Lantheus. MarketBeat recorded 8 mentions for Roivant Sciences and 5 mentions for Lantheus. Roivant Sciences' average media sentiment score of 1.26 beat Lantheus' score of 1.15 indicating that Roivant Sciences is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lantheus
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Roivant Sciences
5 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Lantheus currently has a consensus price target of $88.86, suggesting a potential upside of 3.54%. Roivant Sciences has a consensus price target of $30.55, suggesting a potential upside of 7.87%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Lantheus.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus
0 Sell rating(s)
3 Hold rating(s)

8 Buy rating(s)

0 Strong Buy rating(s)
2.73
Roivant Sciences
1 Sell rating(s)

1 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.75
: Lantheus has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lantheus $1.54B 3.62 $233.56M $3.37 25.47
Roivant Sciences $29.05M 697.72 -$171.98M -$1.17 N/A
: Lantheus has a net margin of 15.15% compared to Roivant Sciences' net margin of -6,079.94%. Lantheus' return on equity of 30.77% beat Roivant Sciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Lantheus 15.15% 30.77% 16.10%
Roivant Sciences -6,079.94% -19.04% -18.15%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	3.62	$233.56M	$3.37	25.47
Roivant Sciences	$29.05M	697.72	-$171.98M	-$1.17	N/A

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	15.15%	30.77%	16.10%
Roivant Sciences	-6,079.94%	-19.04%	-18.15%

Summary

Lantheus and Roivant Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Lantheus compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

: Genmab A/S has a net margin of 25.89% compared to Lantheus' net margin of 15.15%. Lantheus' return on equity of 30.77% beat Genmab A/S's return on equity.
Company Net Margins Return on Equity Return on Assets
Genmab A/S 25.89% 17.35% 11.69%
Lantheus 15.15% 30.77% 16.10%
: Genmab A/S has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Lantheus has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500.
: 7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: In the previous week, Genmab A/S had 9 more articles in the media than Lantheus. MarketBeat recorded 14 mentions for Genmab A/S and 5 mentions for Lantheus. Lantheus' average media sentiment score of 1.15 beat Genmab A/S's score of 0.72 indicating that Lantheus is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Lantheus
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Genmab A/S has higher revenue and earnings than Lantheus. Genmab A/S is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genmab A/S $3.72B 4.61 $963M $1.55 17.76
Lantheus $1.54B 3.62 $233.56M $3.37 25.47
: Genmab A/S presently has a consensus price target of $39.07, indicating a potential upside of 41.94%. Lantheus has a consensus price target of $88.86, indicating a potential upside of 3.54%. Given Genmab A/S's stronger consensus rating and higher probable upside, research analysts clearly believe Genmab A/S is more favorable than Lantheus.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
0 Sell rating(s)
3 Hold rating(s)

7 Buy rating(s)

2 Strong Buy rating(s)
2.92
Lantheus
0 Sell rating(s)

3 Hold rating(s)

8 Buy rating(s)

0 Strong Buy rating(s)
2.73

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	25.89%	17.35%	11.69%
Lantheus	15.15%	30.77%	16.10%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.61	$963M	$1.55	17.76
Lantheus	$1.54B	3.62	$233.56M	$3.37	25.47

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.92
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Genmab A/S beats Lantheus on 9 of the 17 factors compared between the two stocks.

How does Lantheus compare to Summit Therapeutics?

Lantheus (NASDAQ:LNTH) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

: Lantheus has a net margin of 15.15% compared to Summit Therapeutics' net margin of 0.00%. Lantheus' return on equity of 30.77% beat Summit Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Lantheus 15.15% 30.77% 16.10%
Summit Therapeutics N/A -291.24% -243.07%
: Lantheus presently has a consensus price target of $88.86, indicating a potential upside of 3.54%. Summit Therapeutics has a consensus price target of $27.58, indicating a potential upside of 57.26%. Given Summit Therapeutics' higher possible upside, analysts clearly believe Summit Therapeutics is more favorable than Lantheus.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantheus
0 Sell rating(s)
3 Hold rating(s)

8 Buy rating(s)

0 Strong Buy rating(s)
2.73
Summit Therapeutics
2 Sell rating(s)

5 Hold rating(s)

8 Buy rating(s)

2 Strong Buy rating(s)
2.59
: 99.1% of Lantheus shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: Lantheus has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.25, indicating that its share price is 225% less volatile than the S&P 500.
: Lantheus has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lantheus $1.54B 3.62 $233.56M $3.37 25.47
Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A
: In the previous week, Summit Therapeutics had 15 more articles in the media than Lantheus. MarketBeat recorded 20 mentions for Summit Therapeutics and 5 mentions for Lantheus. Lantheus' average media sentiment score of 1.15 beat Summit Therapeutics' score of 0.19 indicating that Lantheus is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lantheus
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Summit Therapeutics
5 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Neutral

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	15.15%	30.77%	16.10%
Summit Therapeutics	N/A	-291.24%	-243.07%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Summit Therapeutics	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	3.62	$233.56M	$3.37	25.47
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Lantheus beats Summit Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Lantheus compare to Viatris?

Viatris (NASDAQ:VTRS) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

: Lantheus has a net margin of 15.15% compared to Viatris' net margin of -24.58%. Lantheus' return on equity of 30.77% beat Viatris' return on equity.
Company Net Margins Return on Equity Return on Assets
Viatris -24.58% 18.11% 7.29%
Lantheus 15.15% 30.77% 16.10%
: Viatris currently has a consensus price target of $14.67, indicating a potential downside of 5.57%. Lantheus has a consensus price target of $88.86, indicating a potential upside of 3.54%. Given Lantheus' stronger consensus rating and higher possible upside, analysts clearly believe Lantheus is more favorable than Viatris.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viatris
1 Sell rating(s)
2 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.43
Lantheus
0 Sell rating(s)

3 Hold rating(s)

8 Buy rating(s)

0 Strong Buy rating(s)
2.73
: 79.9% of Viatris shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 0.3% of Viatris shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: Viatris has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Lantheus has a beta of -0.08, meaning that its stock price is 108% less volatile than the S&P 500.
: Lantheus has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Viatris $14.30B 1.26 -$3.51B -$2.96 N/A
Lantheus $1.54B 3.62 $233.56M $3.37 25.47
: In the previous week, Viatris had 1 more articles in the media than Lantheus. MarketBeat recorded 6 mentions for Viatris and 5 mentions for Lantheus. Lantheus' average media sentiment score of 1.15 beat Viatris' score of 0.59 indicating that Lantheus is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viatris
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lantheus
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-24.58%	18.11%	7.29%
Lantheus	15.15%	30.77%	16.10%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.26	-$3.51B	-$2.96	N/A
Lantheus	$1.54B	3.62	$233.56M	$3.37	25.47

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantheus beats Viatris on 13 of the 16 factors compared between the two stocks.

Get Lantheus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNTH vs. The Competition

Export

Metric	Lantheus	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.71B	$8.27B	$6.25B	$11.77B
Dividend Yield	N/A	2.48%	2.74%	5.26%
P/E Ratio	25.47	119.73	29.25	27.07
Price / Sales	3.62	8.18	504.14	75.42
Price / Cash	13.75	16.86	43.30	53.90
Price / Book	5.22	3.52	9.67	6.69
Net Income	$233.56M	$223.69M	$3.55B	$332.64M
7 Day Performance	2.72%	0.07%	1.70%	2.01%
1 Month Performance	12.77%	10.31%	5.62%	9.19%
1 Year Performance	-20.52%	0.92%	34.42%	39.59%

Lantheus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNTH Lantheus	3.3351 of 5 stars	$85.82 -2.2%	$88.86 +3.5%	N/A	$5.71B	$1.54B	25.47	1,193	Positive News Upcoming Earnings
MRNA Moderna	1.138 of 5 stars	$48.70 -4.0%	$33.87 -30.5%	N/A	$20.04B	$1.94B	N/A	4,700	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
ROIV Roivant Sciences	2.8134 of 5 stars	$27.85 +1.6%	$30.55 +9.7%	N/A	$19.62B	$29.05M	N/A	860	Positive News
GMAB Genmab A/S	4.7151 of 5 stars	$26.64 -0.9%	$39.36 +47.7%	N/A	$17.26B	$3.72B	17.19	3,029	Upcoming Earnings Analyst Revision
SMMT Summit Therapeutics	2.4542 of 5 stars	$22.12 +0.2%	$31.00 +40.1%	N/A	$17.14B	N/A	N/A	110	News Coverage Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNTH) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lantheus (LNTH) Competitors